Sign In
Buy ELDN
$3.81
-0.110 (-2.81%)
At Close: Jun 22, 2026
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
07:00am, Wednesday, 05'th Nov 2025
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at Kidney Week
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
04:05pm, Wednesday, 24'th Sep 2025
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
07:00am, Friday, 29'th Aug 2025
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
04:20pm, Thursday, 14'th Aug 2025
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m 2 post-transplant for patients on tegoprubart Company on track to report topline
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
04:01pm, Wednesday, 06'th Aug 2025
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney functio
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, Augu
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at WTC 2025
Best Momentum Stocks to Buy for July 14th
11:01am, Monday, 14'th Jul 2025
ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.
New Strong Buy Stocks for July 14th
07:10am, Monday, 14'th Jul 2025
WIT, KNOP, PENG, ELDN and KDDIY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2025.
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000 Growth Index
03:16pm, Monday, 30'th Jun 2025
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000 Growth Index
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
04:01pm, Wednesday, 25'th Jun 2025
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 be
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
02:58pm, Friday, 23'rd May 2025
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
04:01pm, Wednesday, 14'th May 2025
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transpla
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet
08:15am, Saturday, 03'rd May 2025
Eledon Pharmaceuticals' lead candidate, tegoprubart, shows promise in improving kidney function post-transplant, potentially becoming the new standard-of-care over tacrolimus. With a significant total
